[go: up one dir, main page]

PE20080400A1 - Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas - Google Patents

Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas

Info

Publication number
PE20080400A1
PE20080400A1 PE2007000865A PE2007000865A PE20080400A1 PE 20080400 A1 PE20080400 A1 PE 20080400A1 PE 2007000865 A PE2007000865 A PE 2007000865A PE 2007000865 A PE2007000865 A PE 2007000865A PE 20080400 A1 PE20080400 A1 PE 20080400A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
contraception
risk
reduce
congenital malformations
Prior art date
Application number
PE2007000865A
Other languages
English (en)
Inventor
Claus Claussen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06016950A external-priority patent/EP1891959A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20080400A1 publication Critical patent/PE20080400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) 2,0 mg DE 17 ALFA- CIANOMETIL-17-BETA-HIDROXIESTRA-4,9-DIEN-3-ONA (DIENOGEST); B) 0,015 mg DE 17ALFA-ETINILESTRADIOL (ETINILESTRADIOL); C) (6S)-5-METIL-TETRAHIDROFOLATO. DICHA COMPOSICION REPRESENTA UN COMPRIMIDO, DE PREFERENCIA UN COMPRIMIDO RECUBIERTO CON UN NUCLEO DE COMPRIMIDO. SE REFIERE ADEMAS A UN KIT QUE CONTIENE 21 UNIDADES DE LA COMPOSICION FARMACEUTICA Y 7 UNIDADES DE DOSIS DIARIAS CON CONTENIDO DE (6S)-5-METILTETRAHIDROFOLATO SIENDO UTILES EN LA ANTICONCEPCION Y PARA REDUCIR EL RIESGO DE MALFORMACIONES CONGENITAS
PE2007000865A 2006-07-06 2007-07-05 Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas PE20080400A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06014002 2006-07-06
EP06016950A EP1891959A1 (de) 2006-08-14 2006-08-14 Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen

Publications (1)

Publication Number Publication Date
PE20080400A1 true PE20080400A1 (es) 2008-07-04

Family

ID=38330771

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000865A PE20080400A1 (es) 2006-07-06 2007-07-05 Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas

Country Status (16)

Country Link
US (1) US20080268048A1 (es)
EP (1) EP2037935A1 (es)
JP (1) JP2009542588A (es)
KR (1) KR20090029824A (es)
AR (1) AR061959A1 (es)
BR (1) BRPI0713999A2 (es)
CA (1) CA2665788A1 (es)
CL (1) CL2007001961A1 (es)
DE (1) DE112007001600A5 (es)
IL (1) IL196154A0 (es)
MX (1) MX2009000256A (es)
PE (1) PE20080400A1 (es)
RU (1) RU2009102443A (es)
TW (1) TW200810764A (es)
UY (1) UY30461A1 (es)
WO (1) WO2008003363A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
MA44205B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
SMT201800232T1 (it) 2015-06-18 2018-07-17 Mithra Pharmaceuticals S A Unita' di dosaggio orodispersibile contenente un componente di estetrolo
EP3310333B1 (en) 2015-06-18 2020-04-29 Estetra SPRL Orodispersible dosage unit containing an estetrol component
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
TR200002995T2 (tr) * 1998-04-17 2001-01-22 Ortho-Mcneil Pharmaceutical,Inc. Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US7696219B2 (en) * 2000-09-27 2010-04-13 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiences in renal patients
US20020147155A1 (en) * 2001-04-06 2002-10-10 Foster Warren G. Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands
US20050164977A1 (en) * 2002-02-21 2005-07-28 Coelingh Bennink Herman J.T. Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12
WO2005115349A1 (de) * 2004-05-28 2005-12-08 Grünenthal GmbH Folsäurehaltiges kontrazeptivum
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
IL196154A0 (en) 2009-09-22
CA2665788A1 (en) 2008-01-10
TW200810764A (en) 2008-03-01
WO2008003363A1 (de) 2008-01-10
DE112007001600A5 (de) 2009-04-30
UY30461A1 (es) 2008-02-29
RU2009102443A (ru) 2010-08-20
JP2009542588A (ja) 2009-12-03
MX2009000256A (es) 2009-02-18
US20080268048A1 (en) 2008-10-30
BRPI0713999A2 (pt) 2012-11-20
AR061959A1 (es) 2008-08-10
KR20090029824A (ko) 2009-03-23
CL2007001961A1 (es) 2008-01-11
EP2037935A1 (de) 2009-03-25

Similar Documents

Publication Publication Date Title
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
AR051397A1 (es) Composicion farmaceutica
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
MY169516A (en) Pharmaceutical composition containing a tetrahydrofolic acid
CL2011003291A1 (es) Composicion farmaceutica de dosis unica que contiene a) como gestageno 50-90 µg de levonorgestrel y b) como inhibidor cox (ciclooxigenasa) 5-60 mg de piroxicam, 50-600 mg de indometacina o 40-450 mg de diclofenaco; y su uso para preparar medicamentos para la anticoncepcion en caso de emergencia.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
SG171649A1 (en) Dpp iv inhibitor formulations
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CO6400186A2 (es) Tabletas de acetato de ulipristal
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
PA8809601A1 (es) Combinación anti-retroviral
MY148723A (en) Use of pinolenic acid for the treatment of obesity
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
ES2720869T3 (es) Composiciones farmacéuticas de sevelámero
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
SG152257A1 (en) Topical preparation containing ambroxol
CL2008003799A1 (es) Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
WO2004071385A3 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
PE20050359A1 (es) Composiciones topicas que comprenden terbinafina e hidrocortisona

Legal Events

Date Code Title Description
FD Application declared void or lapsed